Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Seven pharmaceutical CEOs testify in front of the Senate Finance Committee. Photo: Win McNamee/Getty Images
Seven of the pharmaceutical industry's top CEOs came to Capitol Hill yesterday, spent a few hours pointing the finger at pharmacy benefit managers, and went home largely unscathed.
Between the lines: The pharma CEOs were able to stick to their plan. No one on the Finance Committee backed any of them into a corner, or knocked them very far off their talking points, or made them commit to anything they might regret. Their stocks were unaffected.
- Most notably, the CEOs praised the Trump administration's plan to eliminate PBM rebates in Medicare. But they didn't commit to lowering their list prices as a result; some suggested that might only happen if Congress also eliminates rebates in commercial insurance.
Yes, but: Pharma isn't out of the woods. The headwinds it faced before the hearing — the general political climate, the nascent bipartisan interest in patent reform, and an unpredictable administration — are all still there. And this isn't the end of congressional oversight on drug prices.
My thought bubble: The committee's hearing may not have been industry's dream. In pharma's ideal world, it wouldn't have happened at all. But it was awfully close to the next-best thing.
Go deeper: Pharma's grip on the health care economy